CS
AGIO icon

Candriam SCA’s Agios Pharmaceuticals AGIO Stock Holding History

Candriam SCA’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-169,550
Closed -$5.57M – 675
2024
Q4 		$5.57M Sell
169,550
-91,955
-35% -$4.32M 0.03% 340
2024
Q3 		$11.6M Sell
261,505
-61,377
-19% -$2.79M 0.07% 253
2024
Q2 		$13.9M Buy
+322,882
New +$11.7M 0.08% 215
2023
Q2 		– Sell
-20,160
Closed -$426K – 717
2023
Q1 		$426K Buy
+20,160
New +$535K ﹤0.01% 805
2021
Q2 		– Sell
-241,987
Closed -$10.1M – 888
2021
Q1 		$10.1M Hold
241,987
– – 0.08% 250
2020
Q4 		$10.5M Sell
241,987
-135,618
-36% -$5.36M 0.08% 254
2020
Q3 		$13.2M Buy
+377,605
New +$16.6M 0.12% 183
2016
Q2 		– Sell
-40,000
Closed -$1.61M – 655
2016
Q1 		$1.61M Sell
40,000
-6,600
-14% -$282K 0.04% 354
2015
Q4 		$3.02M Hold
46,600
– – 0.08% 248
2015
Q3 		$3.29M Sell
46,600
-1,400
-3% -$137K 0.08% 260
2015
Q2 		$5.33M Buy
48,000
+23,000
+92% +$2.48M 0.11% 229
2015
Q1 		$2.36M Hold
25,000
– – 0.05% 372
2014
Q4 		$2.8M Buy
+25,000
New +$2.23M 0.06% 315

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Candriam SCA's AGIO Position: Q1 2025 in Review

Candriam SCA sold out of Agios Pharmaceuticals (AGIO) in Q1 2025, closing a stake of 169,550 shares — an estimated $5.57M sold.

Candriam SCA first reported a position in AGIO in Q4 2014 and held it in 13 quarters. The position peaked at $13.9M in Q2 2024. 220 funds tracked by Wall St. Rank hold AGIO as of Q1 2025.

  • Candriam SCA reported no remaining Agios Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Candriam SCA sold 169,550 Agios Pharmaceuticals shares in Q1 2025, an estimated $5.57M.
  • Candriam SCA first reported a position in Agios Pharmaceuticals in Q4 2014 and held it in 13 quarters.
  • Candriam SCA's Agios Pharmaceuticals position peaked at $13.9M in Q2 2024.
  • 220 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2025.

Based on Candriam SCA's 13F filing for Q1 2025, filed 14 May 2025.